Targeted protein degradation: a promise for undruggable proteins

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

Agrifood corporates turn to startups to hedge disruptions and get an edge on trends

Cambridge biotech launches with $50M to target 'junk DNA'

SARS-CoV-2 infected host cell proteomics reveal potential therapy targets

After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work

Vertex, CRISPR’s gene-editing treatment for blood disorders shows promise in early data

SAVE the date 1st ISR-Openscreen workshop and conference

Metabolic landscape of the tumor microenvironment at single cell resolution

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating S

NHS To Create National Artificial Intelligence Lab Following £250 Million Investment Boost

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

Bayer sees potential future business in plant-based meat market

FDA approves Medtronic's 'artificial pancreas,' the world's first

A good glimpse on cell therapy efforts ongoing in oncology

Programmable bacteria induce durable tumor regression and systemic antitumor immunity